Every Form 4 that Valion Bio, Inc. (VBIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VBIO filings page.
Valion Bio, Inc. (symbol: VBIO) is the issuer of record for a Form 4 filing submitted to the SEC. Zikria Dean reported acquisition or exercise transactions in this Form 4 filing.
Valion Bio, Inc. (VBIO) Interim CEO and director Zikria Dean received an award of 50,000 restricted stock units on September 22, 2026. Each unit is convertible into one common share, and one fourth is scheduled to vest quarterly, beginning December 22, 2026. The reported amounts reflect the company’s 1-for-25 reverse stock split on August 31, 2026; Dean’s reported direct RSU holdings following the award were 50,000 units.
Valion Bio, Inc. COO & CFO Lisa G. Wolf reported settlement of 4 restricted stock units for 4 common shares on September 18, 2026. Two common shares were forfeited for tax withholdings, using a market price of $2.12 per share. The reported post-transaction position was 19 restricted stock units. The RSU and tax-withholding counts reflect the 1-for-25 reverse stock split on August 31, 2026; no Rule 10b5-1 plan is reported.
Valion Bio, Inc. Chief Financial Officer Lisa G. Wolf exercised restricted stock units into common shares in a routine compensation-related transaction. She acquired 92 shares of common stock through conversion of 92 Restricted Stock Units, bringing her direct holdings to 618 common shares. Following the transaction, 551 Restricted Stock Units remain outstanding, which continue to vest over time according to a three-year schedule that began on December 18, 2024.
Valion Bio, Inc.’s Chief Executive Officer Michael K. Handley exercised restricted stock units into common shares. On May 18, 2026, he acquired 2,206 shares of common stock through a derivative exercise recorded at $0.00 per share.
Following the transaction, he directly holds 11,030 shares of common stock and 24,265 restricted stock units. Each restricted stock unit converts into one share of common stock under a multi‑year vesting schedule described in the grant terms.